National Screening Institute (NSI) has the exclusive world-wide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium.
What we have to offer: Antibodies for targets that are superior to existing biomarkers. The only blood test that reflects atherosclerotic disease activity in the arterial wall. Diagnostic accuracy that is superior to lipoprotein particle profiles. Standard specimen collection and handling. Proprietary license arrangement. Patent protection. A high market potential.
Test kits are available for clinical use. NSI tests kits are manufactured and distributed by Mercodia AB located in Uppsala, Sweden. About 400,000 patients have been evaluated by pharmaceutical companies and research organizations using Mercodia’s sandwich and competitive microtiterplate assays. While the pharmaceutical studies are confidential, some 400 articles/posters have been published.
Clinical use by physicians: Quest Diagnostics runs the oxidized LDL assay on an automated microtiter system. It should be note that mail-in tests do not require special specimen handling. Future information is available at Quest Diagnostics.
Primary purpose of this information is to provide peer-reviewed data from leading medical journals that demonstrate that (1) native LDL must be converted to oxidized LDL in order to become atherogenic, (2) that oxidized LDL is the culprit molecule directly involved the development and progression of atheroscerotic plaque, (3) that the oxidized LDL assay based on the monoclonal antibody 4E6 is a more accurate marker for coronary artery disease than time-honored conventional lipid and lipoprotein markers, (4) that oxidized LDL is a prognostic marker for the progression of atherosclerosis and acute coronary events, and (5) that oxidized LDL will become the biomarker of choice for the diagnosis and therapeutic monitoring of coronary artery disease.